Two companies, Manhattan Genomics and Bootstrap Bio, which aimed to create gene-edited babies, have shut down due to financial issues and internal conflicts. Manhattan Genomics closed soon after assembling a team of notable scientific advisers, while Bootstrap Bio ceased operations in late 2025. Both companies intended to use germline editing to prevent serious diseases in babies, a controversial practice as changes at the embryo level would be inherited by future generations. This technology is unproven and raises ethical concerns about potential misuse for creating “designer babies.” The practice is banned in the US and many countries. Bootstrap Bio faced additional challenges when its chief science officer was arrested for unrelated criminal charges. Despite initial investor interest, the company struggled to secure enough funding to continue.
QUESTION: How might the ethical concerns surrounding gene editing influence future scientific advancements in medicine?
Designer Baby Companies Are in Turmoil
